Nabbing late-stage drug, PTC acquires gene therapy startup Agilis for $200M in cash/stock
After its bumpy road with a thrice-failed Duchenne drug, the team at PTC Therapeutics has been busy putting new irons in its fire. In its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
